No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Bone marrow transplantation is a costly procedure. Depending on the type of transplant the rate may vary from ₹7 lakh to ₹50 ...